Dr. Vokes on Pembrolizumab Plus Chemotherapy and Radiation in Lung Cancer
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.
According to Vokes, pembrolizumab, chemotherapy, and radiation is a relevant treatment option for patients with lung cancer. There was a trial investigating this for patients with nonsquamous non-small cell lung cancer (NSCLC), which accrued 500 patients. It showed no difference in progression-free survival and overall survival, states Vokes.
